|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2
|
Ekström-Smedby K: Epidemiology and
etiology of non-Hodgkin lymphoma - a review. Acta Oncol.
45:258–271. 2006.
|
|
3
|
Vose J, Armitage J and Weisenburger D;
International T-Cell Lymphoma Project. International peripheral
T-cell and natural killer/T-cell lymphoma study: pathology findings
and clinical outcomes. J Clin Oncol. 26:4124–4130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shiels MS, Engels EA, Linet MS, et al: The
epidemic of non-Hodgkin lymphoma in the United States:
disentangling the effect of HIV, 1992–2009. Cancer Epidemiol
Biomarkers Prev. 22:1069–1078. 2013.PubMed/NCBI
|
|
5
|
Gisselbrecht C, Gaulard P, Lepage E, et
al: Prognostic significance of T-cell phenotype in aggressive
non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte
(GELA). Blood. 92:76–82. 1998.
|
|
6
|
Reimer P, Rüdiger T, Geissinger E, et al:
Autologous stem cell transplantation as first-line therapy in
peripheral T-cell lymphomas: results of a prospective multicenter
study. J Clin Oncol. 27:106–113. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jagadeesh D and Smith MR: Novel targeted
therapies in peripheral T cell lymphoma. Discov Med. 15:367–378.
2013.PubMed/NCBI
|
|
8
|
Somers GF: Pharmacological properties of
thalidomide (alpha-phthalimido glutarimide), a new sedative
hypnotic drug. Br J Pharmacol Chemother. 15:111–116. 1960.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tseng S, Pak G, Washenik K, Pomeranz MK
and Shupack JL: Rediscovering thalidomide: a review of its
mechanism of action, side effects, and potential uses. J Am Acad
Dermatol. 35:969–979. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kruse FE, Joussen AM, Rohrschneider K,
Becker MD and Völcker HE: Thalidomide inhibits corneal angiogenesis
induced by vascular endothelial growth factor. Graefes Arch Clin
Exp Ophthalmol. 236:461–466. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aseffa A, Dietrich MA and Shannon EJ:
Effect of thalidomide on apoptosis of lymphocytes and neutrophils.
Immunopharmacol Immunotoxicol. 19:313–326. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Singhal S, Mehta J, Desikan R, et al:
Antitumor activity of thalidomide in refractory multiple myeloma. N
Engl J Med. 341:1565–1571. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
FDA. FDA Approves Thalomid (thalidomide)
to Treat Multiple Myeloma. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107296.htm.
Accessed May 18, 2014
|
|
14
|
Krown SE: Management of Kaposi sarcoma:
the role of interferon and thalidomide. Curr Opin Oncol.
13:374–381. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kaufmann H, Raderer M, Wöhrer S, et al:
Antitumor activity of rituximab plus thalidomide in patients with
relapsed/refractory mantle cell lymphoma. Blood. 104:2269–2271.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Strupp C, Germing U, Scherer A, et al:
Thalidomide for the treatment of idiopathic myelofibrosis. Eur J
Haematol. 72:52–57. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ramírez J, Wu K, Janisch L, et al: The
effect of thalidomide on the pharmacokinetics of irinotecan and
metabolites in advanced solid tumor patients. Cancer Chemother
Pharmacol. 68:1629–1632. 2011.PubMed/NCBI
|
|
18
|
Swerdlow SH, Campo E, Harris NL, et al:
WHO Classification of Tumours of Haematopoietic and Lymphoid
Tissues. 4th edition. International Agency for Research on Cancer
Press; Lyon: 2008
|
|
19
|
Oken MM, Creech RH, Tormey DC, et al:
Toxicity and response criteria of the Eastern Cooperative Oncology
Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang HQ, Peng YL, Lin XB, et al: Clinical
outcomes of 106 patients with peripheral T-cell lymphoma treated by
standard CHOP regimen. Chin J Cancer. 23(Suppl 11): S1443–S1447.
2004.(In Chinese).
|
|
21
|
Haas PS, Denz U, Ihorst G and Engelhardt
M: Thalidomide in consecutive multiple myeloma patients:
single-center analysis on practical aspects, efficacy, side effects
and prognostic factors with lower thalidomide doses. Eur J
Haematol. 80:303–309. 2008. View Article : Google Scholar
|
|
22
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
|
23
|
NCI. Cancer therapy evaluation program,
common terminology criteria for adverse events. Version 3.0. Dec
12–2003, Available at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
Accessed May 18, 2014
|
|
24
|
Rapisarda A and Melillo G: Role of the
VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res.
114:237–267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Govindarajan R: Irinotecan/thalidomide in
metastatic colorectal cancer. Oncology (Williston Park). 16(Suppl
3): S23–S26. 2002.
|
|
26
|
Majumder S, Sreedhara SR, Banerjee S and
Chatterjee S: TNF α signaling beholds thalidomide saga: a review of
mechanistic role of TNF-α signaling under thalidomide. Curr Top Med
Chem. 12:1456–1467. 2012.
|
|
27
|
Ladizinski B, Shannon EJ, Sanchez MR and
Levis WR: Thalidomide and analogues: potential for immunomodulation
of inflammatory and neoplastic dermatologic disorders. J Drugs
Dermatol. 9:814–826. 2010.PubMed/NCBI
|
|
28
|
Mei SC and Wu RT: The G-rich promoter and
G-rich coding sequence of basic fibroblast growth factor are the
targets of thalidomide in glioma. Mol Cancer Ther. 7:2405–2414.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rafiee P, Stein DJ, Nelson VM, Otterson
MF, Shaker R and Binion DG: Thalidomide inhibits inflammatory and
angiogenic activation of human intestinal microvascular endothelial
cells (HIMEC). Am J Physiol Gastrointest Liver Physiol.
298:G167–G176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lin YC, Shun CT, Wu MS and Chen CC: A
novel anticancer effect of thalidomide: inhibition of intercellular
adhesion molecule-1-mediated cell invasion and metastasis through
suppression of nuclear factor-kappaB. Clin Cancer Res.
12:7165–7173. 2006. View Article : Google Scholar
|
|
31
|
Zhu YX, Kortuem KM and Stewart AK:
Molecular mechanism of action of immune-modulatory drugs
thalidomide, lenalidomide and pomalidomide in multiple myeloma.
Leuk Lymphoma. 54:683–687. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Strupp C, Aivado M, Germing U, Gattermann
N and Haas R: Angioimmunoblastic lymphadenopathy (AILD) may respond
to thalidomide treatment: two case reports. Leuk Lymphoma.
43:133–137. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wilson EA, Jobanputra S, Jackson R, Parker
AN and McQuaker IG: Response to thalidomide in
chemotherapy-resistant mantle cell lymphoma: a case report. Br J
Haematol. 119:128–130. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Damaj G, Lefrère F, Delarue R, Varet B,
Furman R and Hermine O: Thalidomide therapy induces response in
relapsed mantle cell lymphoma. Leukemia. 17:1914–1915. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pro B, Younes A, Albitar M, et al:
Thalidomide for patients with recurrent lymphoma. Cancer.
100:1186–1189. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Su X, Zhang R, Liu H, et al: Clinical
study of E-CHOP plus thalidomide in treatment of advanced
non-Hodgkin’s lymphoma. China Pharmaceuticals. 17:53–55. 2008.
|
|
37
|
Damaj G, Bouabdallah R, Vey N, Bilger K,
Mohty M and Gastaut JA: Single-agent thalidomide induces response
in T-cell lymphoma. Eur J Haematol. 74:169–171. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dogan A, Ngu LS, Ng SH and Cervi PL:
Pathology and clinical features of angioimmunoblastic T-cell
lymphoma after successful treatment with thalidomide. Leukemia.
19:873–875. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tassinari D, Santelmo C, Tombesi P and
Sartori S: Thalidomide in the treatment of cancer cachexia. J
Palliat Care. 24:187–189. 2008.PubMed/NCBI
|
|
40
|
Carrier M, Le Gal G, Tay J, Wu C and Lee
AY: Rates of venous thromboembolism in multiple myeloma patients
undergoing immunomodulatory therapy with thalidomide or
lenalidomide: a systematic review and meta-analysis. J Thromb
Haemost. 9:653–663. 2011. View Article : Google Scholar
|
|
41
|
Zhu D, Corral LG, Fleming YW and Stein B:
Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce
apoptosis of both hematological and solid tumor cells through NK
cell activation. Cancer Immunol Immunother. 57:1849–1859. 2008.
View Article : Google Scholar : PubMed/NCBI
|
